Skip to main content
. 2024 May 1;9(6):e10673. doi: 10.1002/btm2.10673

FIGURE 6.

FIGURE 6

Stratification of active ingredients in clinical trials and FDA approved hemostats for Hemophilia A and B. (a) Proportion of active ingredients for Hemophilia A. (b) Proportion of active ingredients for Hemophilia B. AAV, adeno‐associated virus; HSCs, hematopoietic stem cells; PCC, Prothrombin Complex Concentrate; siRNA, small interfering RNA. TFPI, Tissue Factor Pathway Inhibitor; vWF, von Willebrand factor.